updated 10/8/2009 4:40:42 PM ET 2009-10-08T20:40:42

Federal health advisers said Thursday that Pfizer's HIV drug Selzentry should be approved for use by patients who have not already taken other drugs to combat the virus.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The Food and Drug Administration's panel of virus experts voted 10-4 in favor of the new use, despite some inconsistency in company studies of the drug. Selzentry is approved as a secondary option for HIV patients who are not responding to other antiviral drugs. New York-based Pfizer is asking the FDA to approve the drug as an initial treatment.

Pfizer's initial study comparing Selzentry with Bristol-Myers Squibb's Sustiva failed to meet the goal of showing it was at least as effective at suppressing HIV.

But when Pfizer reanalyzed the results using a different test to screen patients, the study met its goal.

FDA reviewers raised concerns about higher levels of viral activity in patients taking Selzentry compared with Sustiva. About 32 percent of patients did not adequately respond to Pfizer's drug, compared with 24 percent of patients taking the alternative.

A majority of panelists ultimately said the drug works and should be made available as an option for patients, though they expressed lingering concerns about the strength of its effect.

"It's clearly an active drug, it demonstrated effectiveness," said Dr. Russell Van Dyke, of the Tulane University School of Medicine. "But I'm worried it's not as potent as we might like."

Other panelists said they were not comfortable backing a product that could be inferior to drugs already on the market.

"There's a lot that's promising about this drug, but this trial doesn't convince me," said Dr. Barbara McGovern, of Tufts University Medical School.

Panelists said Pfizer should continue collecting data on the drug's effectiveness, particularly in minority populations.

The FDA is not required to follow the advice of its panels, though it usually does.

Selzentry is part of a recently developed class of treatments that block HIV from entering white blood cells through a pathway present in some patients. While more than 1 million people in the U.S. are HIV positive, only a subset of that group respond to Pfizer's pill. The drug works by blocking the so-called CCR5 receptor.

HIV attacks the body's immune system, eventually causing AIDS.

Pfizer said the meeting "marks an important step in expanding available treatment options for patients with HIV infection."

Selzentry had sales of $46 million last year, according to Pfizer.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments